Q-omics provides the consensus-scored AMZ2P1 profile across patient tissues and cancer cell-line models. AMZ2P1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AMZ2P1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, AMZ2P1 RNA expression shows 18,905 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where AMZ2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMZ2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMZ2P1 survival associations across molecular data types. AMZ2P1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMZ2P1 RNA expression–survival associations across cancer types. High AMZ2P1 expression shows unfavorable associations in KIRC, KICH and LIHC, but favorable associations in UCS, BRCA and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AMZ2P1 RNA expression.
This table summarizes AMZ2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AMZ2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMZ2P1 shows lower tumor expression in THCA, UCEC, KICH and BLCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher AMZ2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.361, t-test p < 0.001).
This table shows molecular features associated with AMZ2P1 in patient tissues and cancer cell lines. In patient samples, AMZ2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AMZ2P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS.
